News and Press
Veralox Therapeutics Appoints Life Sciences Industry Veteran Alex Martin as Chairman of the Board of Directors
FREDERICK-(Business Wire)-Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Alex Martin as Chairman of the Board of Directors.
Mr. Martin brings to the Chairman’s role over 25 years of experience in senior executive roles in the life sciences industry, with a focus on business development, operations, and financing. He is currently the Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. Mr. Martin was previously Chief Executive Officer of Realm Therapeutics, which was acquired by ESSA Pharma in July 2019, and has held executive roles at biopharmaceutical companies including Intercept Pharmaceuticals (ICPT) as Chief Operating Officer and BioXell as Chief Financial Officer. He began his career at SmithKline Beecham and later became Vice President, Global Business Development & Licensing at Novartis.
“I am thrilled to welcome Alex as Chairman of our Board of Directors,” said Jeffrey Strovel, PhD, Chief Executive Officer of Veralox. “He is an accomplished industry leader who brings a strong track record in operational, business and drug development experience. Alex’s deep understanding of our industry and keen strategic insights will bring an important perspective to the Board as we transition to a clinical stage company with multiple products in development.”
“It’s an honor to be appointed Chairman and I’m excited for the opportunity to leverage my experience to provide additional perspectives and insights at such an important time in Veralox’s evolution,” added Martin. “Heparin-induced thrombocytopenia (HIT) is a life-threatening disease where the only approved treatment still carries the risk of significant bleeding and mortality, and Veralox’s lead candidate, VLX-1005, could be a game changer for people suffering from this condition. I look forward to working with Jeff and the entire Veralox Board to further develop this opportunity.”
Mr. Martin received his B.A. from Cornell University and an M.B.A. from Harvard University.
About Veralox Therapeutics
VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The company’s lead candidate, VLX-1005, will be developed initially to treat patients with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). Second generation therapeutic products are under development for type 1 diabetes (T1D) as well as other immune-mediated and inflammatory diseases.
Chief Executive Officer of Veralox Therapeutics